AICAR Limited Human Data

What It Is

AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; also called AICA riboside or, as its pharmaceutical formulation, acadesine) is a small-molecule nucleoside analog in which an imidazole-carboxamide base is linked to a ribose sugar. It is a naturally occurring metabolic intermediate in the de novo purine biosynthesis pathway — cells routinely make and handle AICAR and its phosphorylated form as part of purine synthesis.

When AICAR is supplied exogenously (intravenously or subcutaneously), it is taken up by cells via nucleoside transporters and phosphorylated by adenosine kinase to its monophosphate form, ZMP (AICA ribotide). ZMP is a structural mimic of AMP (adenosine monophosphate) and is the pharmacologically active species: it binds the γ-subunit of AMP-activated protein kinase (AMPK) at the same allosteric site that AMP would, causing a conformational change that activates the kinase. From AMPK's perspective, ZMP accumulation looks like an energy crisis — a high AMP / ATP ratio — and it initiates the compensatory energy-generating program.

AICAR's rise to fame in the optimization space stems from a single influential paper: Narkar, Evans and colleagues published "AMPK and PPARδ Agonists Are Exercise Mimetics" in Cell in 2008 (PMID 18674809). That work reported that AICAR administration for four weeks increased running endurance in sedentary adult mice by roughly 44% — the "exercise in a pill" result. The underlying observation is physiologically real but has been frequently over-interpreted; AICAR was shown to reproduce a subset of endurance-training transcriptional adaptations without exercise in sedentary mice and to potentiate exercise training in trained mice. Translating these findings to trained adult humans, at non-ruinous cost and acceptable safety, has not succeeded.

AICAR also has a separate, older therapeutic history under the name acadesine. Large cardiac surgery trials in the 1990s investigated IV acadesine as a cardioprotective agent during coronary artery bypass grafting (CABG). The signal for reduction in myocardial infarction was consistent but modest, and the drug ultimately did not obtain FDA approval for that indication. More recently, acadesine has been explored in chronic lymphocytic leukemia as a modulator of tumor-cell metabolism. Neither indication has yielded an approved product to date.

Mechanism of Action

• Cellular uptake and ZMP formation — AICAR enters cells via equilibrative and concentrative nucleoside transporters and is phosphorylated by adenosine kinase to ZMP. Adenosine kinase activity is the rate-limiting step; in tissues with low adenosine kinase expression, exogenous AICAR produces less ZMP and less AMPK activation.
• AMPK activation via γ-subunit binding — ZMP occupies the AMP binding site on AMPK's γ-regulatory subunit, mimicking the AMP-high / ATP-low energy state and allosterically activating the kinase.
• Phosphorylation of ACC and lipogenic shutdown — Activated AMPK phosphorylates acetyl-CoA carboxylase (ACC), inactivating it and reducing malonyl-CoA production. Lower malonyl-CoA relieves inhibition of carnitine palmitoyltransferase-1 (CPT-1), increasing mitochondrial fatty-acid import and beta-oxidation.
• PGC-1α upregulation / mitochondrial biogenesis — AMPK activation upregulates peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), the master transcriptional regulator of mitochondrial biogenesis. Mitochondrial density in skeletal muscle increases with chronic dosing.
• GLUT4 membrane translocation / insulin-independent glucose uptake — AMPK increases GLUT4 translocation to the sarcolemma independently of the insulin-PI3K-Akt pathway, raising glucose uptake in skeletal muscle. This is the basis for AICAR's acute glucose-lowering effect and its potential diabetes-pharmacology interest.
• mTORC1 suppression — AMPK phosphorylates TSC2 and Raptor, inhibiting mTORC1 signaling. This attenuates anabolic / protein-synthesis signaling and shifts the cellular balance toward catabolism.
• PPARδ cross-talk — The Narkar / Evans 2008 paper demonstrated synergy between AMPK activation and the PPARδ agonist GW501516, with AICAR plus exercise producing the largest effects. PPARδ and AMPK share downstream transcriptional targets (oxidative metabolism, slow-twitch fiber program).
• Muscle fiber-type shift — Chronic AICAR-induced AMPK activation in mice promotes a shift toward slow-twitch oxidative (type I) fiber composition — the fiber type favored by endurance training.
• Autophagy and mitophagy — AMPK phosphorylates ULK1 and Beclin-1, promoting autophagy / mitophagy. This is part of the broader metabolic / stress-response program.
• Cardioprotective adenosine-sparing mechanism (acadesine) — In ischemic tissue, AICAR also acts as an adenosine-regulating agent by modulating adenosine release; this is the proposed mechanism underlying the IV acadesine cardiac-surgery signal (separate from skeletal-muscle AMPK mimicry).

What the Research Shows

• Narkar 2008 (Cell; PMID 18674809) — The definitive exercise-mimetic paper. AICAR administered for 4 weeks increased treadmill running endurance in sedentary adult mice by ~44%. Combined with the PPARδ agonist GW501516, effects were synergistic. In trained mice, AICAR + GW501516 further potentiated endurance. This paper established AICAR as an exercise-mimetic tool compound.
• Merrill 1997 (Am J Physiol; PMID 9435525) — AICAR infusion in isolated rat muscle increases AMPK activity, fatty-acid oxidation, and glucose uptake. Foundational mechanistic paper linking AMPK activation to muscle metabolic adaptations.
• Insulin-independent glucose uptake in diabetic models — Multiple rodent models of type 2 diabetes and obesity show AICAR improves glucose tolerance and insulin sensitivity.
• Cardiac surgery acadesine trials — In the 1990s, several large multicenter trials (Multinational Acadesine Study Group; RED-CABG I/II) evaluated IV acadesine as a perioperative cardioprotective agent during CABG. Results showed a modest, statistically significant reduction in cardiac events (MI, cardiac death). The drug did not ultimately obtain FDA approval for cardioprotection.
• AMPD1 deficiency small trials — Myoadenylate deaminase (AMPD1) deficiency causes exercise intolerance and muscle cramping. Small human studies explored oral AICAR (acadesine) as a metabolic support in affected patients, with mixed effects on exercise tolerance.
• Chronic lymphocytic leukemia (acadesine) — Phase I/II exploration of acadesine as a metabolic therapeutic in CLL (inducing apoptosis in leukemic cells via AMPK-dependent stress pathways). Did not achieve approval.
• Translational ceiling in trained humans — No published randomized placebo-controlled AICAR endurance-performance trial in trained adult humans demonstrates a meaningful VO₂max, time-trial, or ventilatory-threshold benefit at tolerable doses. The mouse endurance signal has not been reproduced in humans.
• Hypoglycemia / lactate / uric acid signals — Preclinical and small human studies consistently show AICAR can cause hypoglycemia, elevated lactate, and elevated uric acid — consequences of the AMP-mimetic mechanism that apply to any AMPK activator.

Human Data

• Acadesine cardiac surgery program — Multiple large multicenter trials (Multinational Acadesine Study Group, RED-CABG) in the 1990s randomized CABG patients to IV acadesine infusion vs placebo. Meta-analyses reported modest reduction in myocardial infarction and cardiac death with acadesine (e.g., Mangano et al., Anesthesiology 1997, meta-analysis of five trials; PMID 9175978). The signal did not survive FDA scrutiny for approval; the drug was not granted marketing authorization for cardioprotection.
• AMPD deficiency small trials — Small open-label and crossover studies in patients with inherited myoadenylate deaminase deficiency explored oral acadesine for exercise-tolerance enhancement. Effects were modest and inconsistent.
• Chronic lymphocytic leukemia Phase I/II — Exploration of acadesine as a metabolic tumor therapy in CLL. Did not yield an approved product.
• Healthy-volunteer pharmacokinetic studies — Small healthy-volunteer IV PK studies document ~1.5 h plasma half-life and intracellular ZMP formation; plasma AICAR clearance is rapid.
• Athletic use detection — AICAR detection methods (LC-MS/MS from urine) were developed by WADA-accredited laboratories around 2010 following the compound's S4 banning. Exogenous AICAR can be distinguished from endogenous AICAR by absolute concentration and pharmacokinetic signature.
• No published endurance-performance RCT in trained humans — There is no Western peer-reviewed randomized placebo-controlled trial establishing AICAR's endurance-performance benefit in trained adult athletes.

Dosing from the Literature

The doses below are drawn from published animal studies, cardiac-surgery trials, and community self-experimentation. No FDA-approved dose exists for metabolic or performance use.

Reconstitution & Storage

AICAR is typically supplied as a lyophilized powder in 50 mg or 100 mg vials. Because AICAR is a small molecule rather than a peptide, some vendors also offer pre-solution forms.

• Reconstitution — AICAR dissolves readily in water or bacteriostatic water. Gentle swirling; avoid foaming.
• Storage — Lyophilized powder stable refrigerated or frozen. Reconstituted solution refrigerated, used within 2–3 weeks.
• Sterility — IV use requires appropriate sterilization and endotoxin testing that research-chemical vendors typically do not provide.
• Identity verification — HPLC / NMR / mass-spec confirmation. AICAR is a defined small molecule with well-characterized analytical profile; purity below 95% should be treated as unacceptable.

→ Use the Kalios Dosing Calculator

Side Effects & Risks

• Hypoglycemia — Dose-dependent drop in blood glucose from AMPK-driven GLUT4 translocation and hepatic gluconeogenesis suppression. Can be clinically significant, particularly in fasted or low-glycogen states.
• Elevated lactate — AMPK shifts metabolism toward glycolysis and increases lactate production. Elevated blood lactate has been documented in both animal and human studies.
• Elevated uric acid — AICAR metabolism and purine flux elevate serum uric acid. Repeated use may precipitate gout in susceptible individuals.
• Cardiac effects — AMPK is highly expressed in cardiac tissue; exogenous activation has complex effects on cardiac rhythm and metabolism. Acadesine cardiac surgery data suggest tolerable at controlled IV rates, but uncontrolled community use lacks that monitoring.
• GI discomfort — Nausea, abdominal discomfort reported at higher doses.
• Injection site reactions — SubQ administration causes local irritation in some users.
• Short half-life limits chronic exposure — Plasma half-life is ~1.5 hours; intracellular ZMP persistence is longer but still short. Sustained AMPK activation requires frequent or continuous dosing, which compounds other adverse effects.
• Cost as risk multiplier — AICAR is synthesis-expensive. Users tempted by lower-cost sources may end up with lower-purity product whose identity is uncertain.
• WADA S4 ban — Athletes in competitive testing pools are subject to sanction for any exogenous AICAR detection. USADA and equivalent bodies have explicit advisories.
• Pregnancy / lactation / pediatric — No safety data. Do not use.
• Drug interactions — Metformin, other AMPK activators (salsalate, aspirin at high dose), thiazolidinediones — additive AMPK effects. Caution with insulin / sulfonylureas (additive hypoglycemia).
• Long-term safety — No chronic-dosing human safety database exists. AMPK activation has complex effects on tissue homeostasis (including tumor-suppressive and, paradoxically in some contexts, tumor-promoting roles depending on metabolic state) — long-term consequences in humans are unstudied.

Bloodwork & Monitoring

• Fasting glucose and insulin — Baseline and periodic. Track changes in insulin sensitivity; watch for hypoglycemia.
• HbA1c — Quarterly for longer-term users.
• Uric acid — Baseline and periodic; elevated uric acid can precipitate gout.
• Lactate — Baseline and periodic if symptomatic; lactate elevations can be clinically significant.
• CMP — Liver and kidney function.
• CBC — Standard periodic screening.
• Body composition — DEXA baseline and follow-up to track fat-mass / lean-mass changes.
• Cardiac — ECG baseline if prior cardiac history; monitor for palpitations or arrhythmia symptoms.
• Lipid panel — Baseline and periodic; track LDL / HDL / triglycerides.
• If athletic testing applies — Do not use. Detection methods are established.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching AICAR often also look at these:

Next Steps

Key References

1. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809. (The definitive "exercise in a pill" mouse endurance paper.)
2. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol. 1997;273(6 Pt 1):E1107-E1112. PMID: 9435525. (Foundational AMPK-activation mechanistic paper.)
3. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229(2):558-565. PMID: 7744080. (Methodology establishing AICAR as the canonical AMPK-activator research tool.)
4. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. JAMA. 1997;277(4):325-332. PMID: 9002496. (Meta-analysis of acadesine cardiac surgery program.)
5. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895-1908. PMID: 21937710. (Authoritative AMPK review by a leading AMPK biochemist.)
6. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994;353(1):33-36. PMID: 7926017. (Early metabolic-effect characterization paper.)
7. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci. 1999;24(1):22-25. PMID: 10087918. (AMPK signaling framework reference.)
8. Van Den Neste E, Cazin B, Janssens A, González-Barca E, Terol MJ, Levy V, Pérez de Oteyza J, Zachee P, Saunders A, de Frias M, Campàs C. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicentre phase I/II study. Cancer Chemother Pharmacol. 2013;71(3):581-591. PMID: 23228967.
9. Sabina RL, Swain JL, Olanow CW, Bradley WG, Fishbein WN, DiMauro S, Holmes EW. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest. 1984;73(3):720-730. PMID: 6707200. (Context for AMPD deficiency indication that drove small acadesine trials.)
10. World Anti-Doping Agency. The 2009 Prohibited List: International Standard. WADA. 2009. (First inclusion of AICAR on the banned list under S4.)
11. Thevis M, Schänzer W. Detection of AICAR - a novel "doping agent"? Methodological developments for mass spectrometric analysis. Drug Test Anal. 2009;1(11-12):523-530. (AICAR doping detection methodology.)
12. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992-1019. PMID: 25216328. (Broader metabolic-modulator context for comparing AMPK-activating approaches with other diabetes-pharmacology strategies.)